Our results also suggest the exciting possibility of using antagonists of activin or its receptors, which are in preclinical or clinical trials for other indications (Chen et al, 2015; Raftopoulos et al, 2016), for skin cancer prevention, for example, through local treatment of skin cancer precursor lesions. This evidence concerns the gene INHBE and skin neoplasm.